Metactive Debuts Novel Embolization Technology
Metactive Medical, Inc., an early-stage company focused on developing endovascular embolization devices for the treatment of neurovascular and peripheral vascular diseases, today presented new nonclinical data on one of its investigational devices at the Society of Interventional Radiology's (SIR) Annual Scientific Meeting. Metactive currently has two devices under development, and today's presentation focused on the company's device that addresses the cerebral aneurysm market. The company's chief executive officer, F. Nicholas Franano, MD, made an oral presentation entitled "Over-the-wire Device for Immediate, Complete and Durable Occlusion of Saccular Cerebral Aneurysms" during the "Arterial Aneurysms and Dissection" session at the meeting.
"Endovascular embolization of cerebral aneurysms with coils was a major advance when it was introduced more than 20 years ago," said Dr. Franano. "The technology that we are developing at Metactive builds upon that innovation by providing a next-generation device that has the potential to provide better patient outcomes, to be faster and easier for physicians to use, and to improve hospital profitability."
Physicians treat approximately 280,000 aneurysms per year worldwide using surgical clips, endovascular coils and flow-diverting stents. Current treatments are complex and costly, and do not consistently result in complete and permanent occlusion of aneurysms. At SIR today, Metactive presented findings from a recent pilot nonclinical study in which the company's cerebral aneurysm embolic device demonstrated immediate and complete mechanical occlusion of a large, terminal saccular aneurysm, as well as full endothelialization and sealing of the aneurysm neck at one month. By comparison, in the same aneurysm model, treatment using widely used conventional coils did not provide immediate and complete occlusion. Compared to coiling, the procedure to place Metactive's device took half as long, and the devices cost one-third as much. While Metactive has only completed a handful of nonclinical procedures to date, these excellent early results support further investigation.
"If Metactive can demonstrate that this new device can provide better clinical outcomes with much lower procedure time and complexity, and large reductions in cost, then I believe it has the potential to provide real value for patients, physicians, hospitals and payers -- especially for large aneurysms," said Kieran Murphy, MD, interventional neuroradiologist and professor of radiology at the University Health Network Toronto in Ontario, Canada, and director of clinical faculty at the Techna Research Institute.